Evidence Regarding Duchenne Muscular Dystrophy Newborn Screening

Area of Science:

• Genetics
• Neuromuscular Disorders
• Public Health

Background:

• Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked genetic disorders caused by variants in the DMD gene.
• DMD affects approximately 2 in 10,000 newborn males, leading to progressive muscle weakness and premature death, often from respiratory or cardiac issues.
• The average diagnostic age in the US is 4.5-5 years, prompting advocacy for newborn screening (NBS) due to the availability of targeted therapies and the challenges of the diagnostic odyssey.

Purpose of the Study:

• To review the current landscape and rationale for implementing newborn screening for Duchenne muscular dystrophy.
• To discuss the diagnostic methods, challenges, and potential benefits of early identification through NBS.
• To contextualize NBS within the evolving treatment paradigms for DMD.

Main Methods:

• Review of existing literature and advocacy for DMD NBS.
• Description of the biochemical marker (creatine kinase, CK-MM) used in screening.
• Explanation of confirmatory molecular genetic analysis for DMD and BMD variants.

Main Results:

• Caregiver studies indicate support for DMD NBS.
• Ohio and Minnesota have implemented DMD NBS, with other states considering it.
• Screening accuracy is dependent on the employed testing algorithm.

Conclusions:

• Newborn screening for DMD offers the potential for earlier diagnosis and intervention.
• While treatments like glucocorticoids, gene therapy, and exon-skipping medications exist, their optimal use and definitive clinical benefits are still under investigation.
• Early identification via NBS is crucial for maximizing the potential benefits of emerging therapies for DMD.